EU Lists Spinal Cord Inflammation Probable Side Effect Of JNJ's COVID-19 Shot: Reuters

• European Medicines Agency (EMA) recommended adding transverse myelitis, a rare type of spinal inflammation, as a side-effect of the Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine.

• Giving updates on the safety of all coronavirus shots, the EMA said it was assessing reports of capillary leak syndrome, a rare blood condition after Moderna Inc's (NASDAQ: MRNA) vaccine.

• The EMA said it had recorded six cases of capillary leak syndrome and was assessing all data, but it was not yet clear if there was a causal association between the reports and the vaccine.

• The EMA said there was insufficient evidence of a possible link between rare cases of the multisystem inflammatory syndrome and mRNA-based vaccines from Moderna and Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) vaccine.

• Price Action: JNJ shares traded lower by 0.83 at $162.90 on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Moderna Says COVID-19 Vax Associated With Fewer Cases Than Pfizer's, But Higher Inflammatory Heart Conditions

• Oklahoma Supreme Court Overturns Opioid Ruling Against Johnson & Johnson

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.